Methods and agents that enhance myogenic progenitor cell engraftment
AssigneesPresident and Fellows of Harvard College, Children's Medical Center Corporation
InventorsSahar Tavakoli, Amy J. Wagers, Leonard Zon
Life of this patent
Estimating the term…
Abstract
Disclosed herein are agents that enhance muscle stem cell engraftment, as well as methods and compositions using the same.
Claims20
A method of increasing the engraftment efficiency of myogenic progenitor cells comprising contacting the myogenic progenitor cells with one or more agents that increase the engraftment efficiency of the myogenic progenitor cells into a subject, wherein the agent is selected from a compound that increases intracellular Ca2+ levels in myogenic progenitor cells, meclofenamic acid (MFA), lysophosphatidic acid (LPA), and niflumic acid (NFA).
A method of enhancing tissue culture of muscle tissue, comprising adding one or more agents that increase the engraftment efficiency of myogenic progenitor cells into the muscle tissue, wherein the agent is selected from a compound that increases intracellular Ca2+ levels in myogenic progenitor cells, Ionomycin, meclofenamic acid (MFA), lysophosphatidic acid (LPA), and niflumic acid (NFA).
A method of screening for a test agent that enhances engraftment of myogenic progenitor cells comprising contacting the test agent with a population of myogenic progenitor cells, adding the contacted myogenic progenitor cells to a muscle tissue, and comparing engraftment into the muscle tissue of the contacted myogenic cells to engraftment into the muscle tissue of control myogenic progenitor cells not contacted with the test agent, thereby determining whether the test agent enhances engraftment.
A composition comprising myogenic progenitor cells and one or more agents that enhances engraftment of the myogenic progenitor cells into muscle tissue, wherein the agent is selected from a compound that increases intracellular Ca2+ levels in myogenic progenitor cells, Ionomycin, meclofenamic acid (MFA), lysophosphatidic acid (LPA), and niflumic acid (NFA).
A composition comprising a therapeutically effective amount of one or more agents that increase the engraftment efficiency of myogenic progenitor cells into muscle tissue of a subject and a pharmaceutically acceptable diluent or excipient, wherein the agent is selected from a compound that increases intracellular Ca2+ levels in myogenic progenitor cells, Ionomycin, meclofenamic acid (MFA), lysophosphatidic acid (LPA), and niflumic acid (NFA).
Dependencies are inferred from the claim text.